Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 2 de 2
Filtre
1.
Indian J Hum Genet ; 2013 Oct-Dec ;19 (4): 408-411
Article Dans Anglais | IMSEAR | ID: sea-156605

Résumé

OBJECTIVES: Estrogen is one of the most crucial hormones participating in the proliferation and carcinogenesis of the prostate glands. Genetic polymorphisms in the estrogen metabolism pathway might be involved in the risk of prostate carcinoma development. We evaluated the association between genetic polymorphisms in estrogen receptor alpha (ESR1) and catechol‑O‑methyltransferase (COMT) genes and the risk of developing familial prostate carcinoma. MATERIALS AND METHODS: In this study, 34 cases with prostate carcinoma whose first‑degree relatives had prostate carcinoma and 30 healthy age‑matched male controls were enrolled. The genotypes of ESR1 and COMT genes were analyzed employing polymerase chain reaction‑restriction fragment length polymorphism method. 34 cases with prostate carcinoma, whose first degree relatives had prostate carcinoma and 14 age‑matched male controls were enrolled to analyze the genotype of these two genes. RESULTS: Among control patients, the ESR1 PvuII genotypes of C/C, C/T and T/T were observed in 37%, 26% and 37%, respectively, whereas the C/C, C/T and T/T genotypes were observed in 18%, 41% and 41% of case patients, respectively. Among controls, the ESR1 PvuII allele frequencies of C and T were equally observed, whereas the C and T allele frequencies were observed in 38% and 62% of patients, respectively. Among ESR1 PvuII genotypes there were not any significant difference in terms of genotype (P = 0.199) and allele (P = 0.181) frequencies. Among controls, the ESR1 XbaI genotypes of G/G, G/A and A/A were observed in 33%, 37% and 33%, respectively, whereas the G/G, G/A and A/A genotypes were observed in 12%, 47% and 41% of patients, respectively. Among controls, the ESR1 XbaI allele frequencies of A and G were observed equally, respectively, whereas the A and G frequencies were observed in 65% and 35% of patients, respectively. Among ESR1 × baI, there was not any significant difference in terms of genotype (P = 0.111) and allele (P = 0.093) frequencies. But the C/C genotype of the PvuII site and G/G genotype of the XbaI site in the ESR1 gene were associated significantly with the risk of developing prostate carcinoma. The G/G, G/A and A/A genotypes of the COMT gene were observed in 50%, 29% and 21% of control patients and in 53%, 21% and 26% of case patients, respectively. The A and G allele frequencies of the COMT gene were observed in 36.7%, 63.3% of control patients and in 36.8%, 63.2% of case patients, respectively. In COMT gene, there was not any significant difference in terms of genotype (P = 0.843) and allele (P = 0.991) frequencies. But the G/A genotype of the COMT gene had a weak tendency toward increased risk. CONCLUSION: Polymorphisms of ESR1 gene in the estrogen metabolism pathway were associated significantly with familial prostate carcinoma risk. Single nucleotide polymorphisms of low‑penetrance genes are targets for understanding the genetic susceptibility of familial prostate carcinoma.


Sujets)
Catechol O-methyltransferase/génétique , Récepteur alpha des oestrogènes/génétique , Famille/histoire , Prédisposition génétique à une maladie/génétique , Humains , Mâle , Tumeurs de la prostate/épidémiologie , Tumeurs de la prostate/génétique , Polymorphisme génétique , Polymorphisme de nucléotide simple , Turquie/épidémiologie
2.
Int. braz. j. urol ; 38(1): 122-128, Jan.-Feb. 2012. graf, tab
Article Dans Anglais | LILACS | ID: lil-623324

Résumé

PURPOSE: The efficacy of three different analgesic techniques during transrectal ultrasound (TRUS) guided prostate biopsy, including (i) periprostatic blockage (PPB), (ii) intrarectal gel instillation, and (iii) sedoanalgesia were compared. MATERIAL AND METHODS: During a period of five months, 100 consecutive men were enrolled in this study. A 10-point linear visual analogue scale (VAS) was used to assess the pain scores during (VAS 1), immediately after (VAS 2) and one hour after (VAS 3) the needle biopsy procedure. The relationship between the level of pain, prostate volume, age and PSA was determined. RESULTS: There were no statistically significant differences between the four groups in terms of mean age and PSA values. The pain scores were significantly lower in sedoanalgesia and PPB groups (p = 0.0001). There was no statistically significant difference between the groups in terms of complications. CONCLUSIONS: In this study, it was shown that patient comfort is better and it is possible to get decreased pain scores with PPB or sedoanalgesia. However, PPB is a preferable method in TRUS-guided prostate biopsy since it is much more practical in outpatient clinics.


Sujets)
Sujet âgé , Sujet âgé de 80 ans ou plus , Humains , Mâle , Analgésie/méthodes , Anesthésiques locaux/administration et posologie , Cytoponction sous échoendoscopie/effets indésirables , Bloc nerveux/méthodes , Prostate/anatomopathologie , Tumeurs de la prostate/anatomopathologie , Administration par voie orale , Administration par voie rectale , Analgésie/normes , Cytoponction sous échoendoscopie/méthodes , Mesure de la douleur , Antigène spécifique de la prostate , Prostate , Tumeurs de la prostate , Échographie interventionnelle
SÉLECTION CITATIONS
Détails de la recherche